Overview
- Biote forecasted 2026 revenue above $190 million and adjusted EBITDA over $38 million while assuming a mid to high single-digit decline in procedure revenue for the full year.
- Biote expanded its sales team from roughly 60 to more than 90 in 2025 and plans to reach about 120 by year-end 2026, supported by investment in a new practitioner technology platform.
- Biote recorded a $1.3 million inventory charge tied to a voluntary recall of certain hormone pellet lots shipped by Asteria Health and is working with the FDA on returns and refills, with management flagging potential near-term gross margin pressure from product mix.
- Harvard Bioscience reported 27% year-over-year adjusted EBITDA growth in Q4 on a shift toward higher-margin offerings, with consumables, services and software now about 55% of revenue.
- Harvard Bioscience guided to 2%–4% revenue growth and 6%–10% adjusted EBITDA growth in 2026, expecting NIH funding approved in February to bolster orders beginning late Q1 with primary revenue benefits in Q2, and planning manufacturing consolidation from Holliston to Minneapolis and European sites to deliver longer-term savings.